Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Natural compound PEITC inhibits gain of function of p53 mutants in cancer cells by switching YAP-binding partners between p53 and p73.

Acta pharmacologica Sinica - 1 Jun 2025

Wang Yi-Xuan, Wang Li-Wei, Huang Ying, Zhou Lin, Li Guo-Yu, Yang Jia-Wen, Wu Xue-Feng, Cheng Jing-Cai, Xu Qiang, Shen Yan

Abstract excerpt

Phenethyl isothiocyanate (PEITC) derived from cruciferous vegetables has shown anticancer activities by modulating apoptosis, cell cycle arrest, drug-metabolizing enzymes and even preferentially restoring a 'WT-like' conformation to p53R175H. But its molecular anti-cancer mechanisms are not well understood. Evidence shows that switching YAP-binding partners from pro-tumorigenic to pro-apoptotic proteins might...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Proteins, Signal Transducing
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to Isothiocyanates

Share to Phosphoproteins

Share to Tumor Protein p73

Share to Tumor Suppressor Protein p53

Share to YAP-Signaling Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 39930134
DOI: 10.1038/s41401-025-01474-1
PMCID: PMC12098782

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Natural compound PEITC inhibits gain of function of p53 mutants in cancer cells by switching YAP-binding partners between p53 and p73.PMID 39930134Read ↗

Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth.Semantic proximity Read ↗

Drugs Targeting p53 Mutations with FDA Approval and in Clinical TrialsSemantic proximity Read ↗

Targeting Oncogenic Mutant p53 for Cancer TherapySemantic proximity Read ↗

The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy - Drug RepurposingSemantic proximity Read ↗

A selective p53 activator and anticancer agent to improve colorectal cancer therapySemantic proximity Read ↗

Targeting Mutant-p53 for Cancer Treatment: Are We There Yet?Semantic proximity Read ↗

Natural Modulators of the TP53 Pathway: Potential Herbal and Plant-Derived Agents for Cancer Therapy.Semantic proximity Read ↗

Innovative Drug and Prodrug Candidates in Cancer Treatment Targeting TP53 Mutations: Challenge and Hope.Semantic proximity Read ↗

p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.Semantic proximity Read ↗

Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic ApproachesSemantic proximity Read ↗

Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis.Semantic proximity Read ↗

p73 as a Pharmaceutical Target for Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.